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A subset of low density 
granulocytes is associated with 
vascular calcification in chronic 
kidney disease patients
Javier Rodríguez-carrio1,2, Natalia carrillo-López2,3, Catalina Ulloa4, Mariana Seijo2,5, 
Minerva Rodríguez-García3,4, Carmen Rodríguez-Suárez4, Carmen Díaz-corte3,4, 
Jorge B. cannata-Andía2,3,6, Ana Suárez  1 & Adriana S. Dusso2,3
Inflammation is central to chronic kidney disease (CKD) pathogenesis and vascular outcomes, but the 
exact players remain unidentified. Since low density granulocytes (LDGs) are emerging mediators in 
inflammatory conditions, we aimed to evaluate whether LDGs may be altered in CKD and related to 
clinical outcomes as biomarkers. To his end, LDGs subsets were measured in peripheral blood by flow 
cytometry and confocal microscopy in 33 CKD patients undergoing peritoneal dialysis and 15 healthy 
controls (HC). Analyses were replicated in an additional cohort. DEF3 (marker of early granulopoiesis) 
gene expression on PBMCs was quantified by qPCR. Total CD15+ LDGs and both CD14lowCD16+ and 
CD14−CD16− subsets were expanded in CKD. The relative frequency of the CD14−CD16− subpopulation 
was higher among the CD15+ pool in CKD. This alteration was stable over-time. The increased 
CD14−CD16−CD15+ paralleled Kauppila scores and DEF3 expression, whereas no association was found 
with CD14lowCD16+ CD15+. Both subsets differed in their CD11b, CD10, CD35, CD31, CD62L, IFNAR1 
and CD68 expression, FSC/SSC features and nuclear morphology, pointing to different origins and 
maturation status. In conclusion, LDGs were expanded in CKD showing a skewed distribution towards a 
CD14−CD16−CD15+ enrichment, in association with vascular calcification. DEF3 expression in PBMC can 
be a marker of LDG expansion.
Chronic Kidney Disease (CKD) is a disorder characterized by premature and exacerbated multi-organic aging1. 
As a consequence, CKD patients develop a number of senescence-related clinical outcomes, such as atherosclero-
sis, osteoporosis, soft tissue calcifications, sarcopenia, frailty, infections, oxidative stress, etc. Importantly, vascular 
calcification (VC) in CKD patients is a main determinant of their increased risk of cardiovascular (CV) death 
compared to the general population2–4.
Chronic and dysregulated inflammation plays a pivotal role in CKD progression, although the exact inflam-
matory mediators remain unclear at present. Inflammatory pathways are key factors for VC5,6, an important 
hallmark of CKD. Of note, inflammation is considered a major part of the aging process and recent studies have 
brought to light its involvement in CV outcomes7,8. Most vascular risks in CKD seem to be attributed to medial 
calcification rather than atherosclerosis occurrence (reviewed in9). However, immune circuits associated with VC 
in CKD are poorly understood. Unravelling immune mediators that underlie VC in CKD is of upmost relevance 
both from the basic perspective as well as for the clinical translation of such findings. In this scenario, myeloid 
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populations have been partially neglected in CKD and VC. Importantly, novel aspects of granulocyte biology have 
emerged in recent years.
A major novel breakthrough in the field was the discovery of the enormous heterogeneity among granulo-
cytes10,11. Additionally, granulocytes are now recognized as immune cells that can perform complex activities, 
orchestrate the immune response via several mediators and cytokines and establish a complex crosstalk with 
components of the innate and adaptive response12,13. In this scenario, a novel subset of granulocytes, the low 
density granulocytes (LDGs) are emerging as relevant players in a wide range of immune-based conditions14–17. 
LDGs are defined by their ability to sediment in the PBMC fractions upon gradient centrifugation of whole 
blood and to exhibit granulocyte markers. Nevertheless, a precise phenotypic definition of LDGs is lacking. 
LDGs have received a notable attention since their frequency has been related to disease severity and clinical 
outcomes in a number of conditions (reviewed in17). Among these conditions, systemic lupus erythematosus has 
been hallmarked by a noticeable LDG expansion17,18. Interestingly, a recent study has found an upregulation of 
a granulocyte-related gene, the defensing 3 (DEF3A) in PBMC isolates from patients19. Although these lines of 
evidence may suggest that DEF3A could be a promising candidate of LDGs expansion, this potential connection 
has not been studied.
However, whether LDGs may be involved in CKD outcomes is yet to be clarified. Therefore, in the present 
study we aimed (i) to evaluate LDGs frequency in CKD patients, (ii) to analyze the associations between LDGs 
and clinical features in this condition as well as their role as a biomarker and (iii) to assess the LDGs phenotype 
in CKD.
Results
LDG expansion in CKD patients. The presence of LDGs was evaluated in a group of 33 CKD5-PD patients 
and 15 HC (Table 1). The LDG population clearly segregated from the monocytes and lymphocytes subsets within 
the PBMC fraction by its side scatter signal (Fig. 1A). LDGs also clearly differed from monocytes by the expres-
sion of HLA-DR, their FCS/SSC signal as well as by the granulocyte marker CD15 (Fig. 1B,C). Additionally, 
CD15+ cells were negative for Siglec8 expression (Fig. 1C), thus ruling out the possibility of these cells to be eosin-
ophils. Interestingly, two different subsets were observed when the CD14 expression was analyzed, in a similar 
way than that of CD16. As a consequence, two subpopulations could be distinguished within the CD15+ LDG 
population: CD14−CD16−CD15+ and CD14lowCD16+ CD15+ (Fig. 1D).
CKD5-PD patients exhibited a higher frequency of LDGs within the mononuclear fraction than HC, and 
higher levels were observed for both CD14lowCD16+ CD15+ and CD14−CD16−CD15+ subsets (Fig. 2A). None 
of the LDG subsets were related to age, time on dialysis, medications or circulating cytokines (all p > 0.050). 
HC (n = 15)
CKD5-PD patients 
(n = 33) p-value
Age, years, mean (range) 48.00 (22.00–68) 55.00 (21.00–77.00) 0.070
Gender, f/m 10/5 13/20 0.080
Clinical features
Albumin, mg/dl 44.17 ± 1.95 34.37 ± 4.35 <0.001
Urea, mg/dl 33.46 ± 8.08 132.66 ± 43.76 <0.001
Creatinine, mg/dl 0.78 ± 0.17 7.81 ± 2.72 <0.001
Plasma Ca, mmol/l 2.34 ± 0.07 2.17 ± 0.16 <0.001
Plasma phosphate, mmol/l 1.04 ± 0.18 1.64 ± 0.42 <0.001
PTH, pg/ml 49.60 ± 15.52 371.03 ± 198.61 <0.001
25(OD)-vitamin D, ng/ml 32.93 ± 15.38 10.10 ± 6.89 <0.001
CRP, mg/dl 0.64 ± 0.86
Vascular calcifications, n(%) 18 (54.5)
Kauppila score 7.88 ± 8.98
Time on dialysis, months 15.00 (16.00)
Treatments, n(%)
Paricalcitol 15 (45.4)





IL-2 1.30 (1.91) 1.60 (0.70) 0.342
IL-6 4.73 (4.58) 6.77 (10.07) 0.154
IL-10 1.49 (0.80) 1.77 (1.05) 0.101
IFNγ 8.32 (6.80) 12.82 (6.57) 0.183
TNFα 8.38 (7.66) 14.01 (6.38) 0.211
Table 1. Demographical, clinical and immunological characteristics of individuals recruited for this study.
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Moreover, no differences in circulating neutrophils were observed between patients and controls and none of 
the LDG subsets were correlated to neutrophil absolute counts (all p > 0.050). Interestingly, within the CD15+ 
total population, the relative frequency of the CD14−CD16− subset was increased in patients compared to 
HC (24.59 ± 19.50 vs. 12.21 ± 10.12, p = 0.012), thus pointing to a skewed profile of the LDG pool in CKD. 
Additionally, a subgroup of patients (n = 8) was re-sampled after 6 months, and LDGs frequency and their rela-
tive distribution in the LDG pool were maintained over this period (Fig. 2B).
Interestingly, CD14−CD16−CD15+ expansion was restricted to patients with vascular calcifications 
(VC, Kauppila scores > 5) compared to VC-free patients (1.29 ± 1.09 vs. 0.41 ± 0.33%, p = 0.010) and HC 
(0.34 ± 0.26%, p = 0.009), whereas this effect was not observed in the CD14lowCD16+ CD15+ subpopulation 
(p = 0.245 and p = 0.145, respectively). In fact, the frequency of CD14−CD16−CD15+ LDGs was strongly corre-
lated to Kauppila scores in the whole patient group (Fig. 2C). Importantly, whereas the CD14lowCD16+ CD15+ 
frequency strongly mirrored that of total CD15+ LDGs, this was not the case for CD14−CD16−CD15+, which 
exhibited a different distribution (Fig. 3A,B).
Furthermore, to gain insight into the LDG expansion, the gene expression of DEF3 (a granulocyte-restricted 
gene among blood cells) was measured in PBMC fractions. CKD5-PD patients exhibited a higher DEF3 expres-
sion compared to HC, which did not reach statistical significance (1.02(2.56) vs. 0.55(0.76) relative units, 
p = 0.128). Surprisingly, DEF3 expression was strongly correlated with the CD14−CD16−CD15+ subset but not 
with the CD14lowCD16+ CD15+ subpopulation (Fig. 2D). DEF3A expression was in turn associated with the 
Kauppila score (r = 0.501, p = 0.006).
Figure 1. Gating strategy for LDG identification and quantification. (A) LDG (arrows) were identified by 
their FSC/SSC properties in PBMC fractions. Representative dot plots from a HC (left) and a CKD5-PD 
patient (right) are shown. (B) LDGs were first identified by their CD15 expression. (C) Histograms showing 
the analyses of the expression of Siglec8 (isotype control: dotted black line, CD15+ population: gray line) and 
HLA-DR (isotype control: dotted black line, CD15+ population: gray line, monocytes: black line). (D) Two 
subsets of LDGs were distinguished within the total CD15+ population based on their CD14 (left dot-plot) and 
CD16 (right dot-plot) expression: CD14−CD6−CD15+ and CD14lowCD16+CD15+.
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Figure 2. LDG subsets in CKD5-PD patients and their association with clinical features. (A) The frequencies of 
total CD15+ LDGs as well as CD14−CD6−CD15+ and CD14lowCD16posCD15+ subsets in PBMC fractions were 
compared between HC (open circles) and CKD5-PD patients (black circles). Central bars represent the median 
values whereas whiskers represent 25th and 75th percentiles. Differences between groups were assessed by Mann-
Withney U tests (*p < 0.050, **p < 0.010, ***p < 0.001). (B) Analyses of LDG subsets in paired samples (n = 8) 
at baseline (t = 0) and after 6 months (t = 6). LDG frequencies are expressed as bars and scatter plots for each 
time point. Differences were assessed by Wilcoxon test for paired samples. Association of the LDG subsets with 
Kauppila scores (C), DEF3 (D) and CD10 (E) gene expression in PBMC fractions. Correlations were assessed by 
Spearman’s rank test.
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Similarly, the gene expression of CD10 (a well-known marker of mature neutrophils) was analyzed in 
PBMC fractions. CD10 expression paralleled total CD15+ LDGs levels (Fig. 2E). However, this correlation 
was observed to be driven by the CD14lowCD16+ CD15+ subset, whereas no association was found with their 
CD14−CD16−CD15+ counterparts.
Finally, a replication cohort consisting on 16 CKD patients undergoing hemodialysis (CKD-5HD) and 6 age- 
and gender-matched controls were recruited to validate our findings. The independent analysis of this cohort 
confirmed all of our previous results (Supplementary Fig. 1). No differences were observed between dialysis 
modalities.
The ability of CD14−CD16−CD15+ LDGs as a biomarker to identify VC was tested by ROC curves. 
Interestingly, an AUC [95% CI] of 0.769 [0.613, 0.924] (p = 0.006) was obtained for the CKD5-PD cohort. This 
was confirmed in the CKD5-HD group (0.803 [0.622, 0.984], p = 0.014). A pooled analysis confirmed a good 
discriminative power of CD14−CD16−CD15+ LDGs as a biomarker in CKD (Fig. 3C). Moreover, not only it was 
identified as an independent predictor but also the frequency of CD14−CD16−CD15+ LDGs improved the ability 
of age and time on dialysis to predict VC when included in combined indices (Fig. 3C). Finally, multiple logistic 
regression analysis confirmed that CD14−CD16−CD15+ LDGs were independent predictors of VC (OR [95% CI], 
p: 1.112 [1.012–9.175], p = 0.020) after adjusting for age, gender and time on dialysis as confounders.
Taken together, these results suggest that CKD is hallmarked by a systemic LDG expansion that is stable over 
time. LDGs in CKD patients are a heterogeneous population, the CD14−CD16−CD15+ subset being associated 
with calcification, thus supporting its role as an independent biomarker. DEF3 expression in the PBMC fraction, 
which parallels CD14−CD16−CD15+ levels, could be considered as a surrogate marker of CD14−CD16−CD15+ 
levels and thus, a biomarker of VC.
Resolving the LDG heterogeneity in CKD. In order to gain insight into the heterogeneity observed 
within the LDG pool in CKD, an extensive immune-phenotyping of these populations and of mature neutrophils 
was carried out.
Interestingly, the CD14lowCD16+ CD15+ subset exhibited an increased expression of mature and activated 
granulocyte markers (CD11b, CD10, CD35, CD31, CD62L and IFNAR1), whereas the CD14−CD16−CD15+ 
subpopulation exhibited a higher expression of CD66b and CD68, the latter being a marker of intermediate 
and early stages of neutrophil differentiation (Fig. 4A,B). As a consequence, the CD14lowCD16+ CD15+ subset 
exhibited a profile that resemble that of mature neutrophils (Fig. 4C), whereas a distinct one was observed for 
their CD14−CD16−CD15+ counterparts. Additionally, these two subsets also differed in their size (FSC) and 
granularity (SSC) features (Fig. 4D).
Figure 3. LDG subsets as biomarkers. (A,B) Associations of the frequency of the CD14−CD16−CD15+ 
population with other LDG subsets and clinical features. Variables were plotted in heatmaps (A, ranked by 
CD15+ LDG frequency; B, ranked by CD14−CD16−CD15+ frequency). Each row of the heatmaps represents 
a study subject. Colors in the vertical left bar denoted HC (blue), CKD5-PD patients (brown) or CKD5-HD 
patients (orange). Tiles are colored based on variable levels, red and blue indicating low or high levels 
respectively, as indicated in the legend (top left). (C) ROC analyses of the role of CD14−CD16−CD15+ as a 
biomarker to predict VC. ROC curves were plotted and AUC, 95% CI and p-values were computed (table).
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Figure 4. Phenotype of LDG subsets in CKD. (A) CD14−CD6−CD15+ (orange) and CD14lowCD16posCD15+ 
(blue) subsets were selected based on the previous gating strategy. (B) The expression of several granulocyte 
markers was analyzed by flow cytometry and compared among LDG subsets and mature neutrophils (black). 
Expression levels are shown as box plots, where the boxes represent the 25th and 75th percentiles, the lines within 
the boxes representing the median and the lines outside the boxes represent the minimum and maximum values. 
Differences were assessed by Kruskal-Wallis tests with Dunn-Bonferroni correction for multiple comparisons’ test. 
(C) Representative histograms for granulocyte markers (gray: isotype control, orange: CD14−CD6−CD15+ subset, 
blue: CD14lowCD16posCD15+ subset and black: mature neutrophils). (D) Differences in FSC and SSC parameters 
between both LDG subsets. Expression levels are shown as box plots, where the boxes represent the 25th and 
75th percentiles, the lines within the boxes representing the median and the lines outside the boxes represent the 
minimum and maximum values. Differences were assessed by Mann-Withney U tests or paired tests (Wilcoxon’s 
test). *p < 0.050, **p < 0.010, ***p < 0.001.
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The phenotype of the LDGs was also confirmed by fluorescence confocal microscopy (Fig. 5). In CD15+ 
enriched fractions, both CD14lowCD16+ CD15+ and CD14−CD16−CD15+ subsets were identified, CD14/CD10 
and CD16 co-expression being confirmed in the former (Fig. 5A). Interestingly, CD14 expression was observed 
to be lower than other markers, such as CD10, in accordance to the CD14low expression detected by flow cytom-
etry. The analysis of cell morphology (Fig. 5B) confirmed that LDGs were bigger than lymphocytes (as revealed 
by flow cytometry) and exhibited a complex membrane, in accordance with the SSC signal. Differences in the 
nucleus were also evident between LDGs and lymphocytes. Furthermore, examination of the nuclear morphology 
by DAPI counterstaining confirmed the complex structure of the LDGs nuclei (Fig. 5C). Importantly, different 
nuclear morphologies could be distinguished: CD16+ LDGs were more likely to exhibit a polymorphonuclear 
morphology, whereas those lacking CD16 expression exhibited a less segmented profile (bi-lobular, indented or 
band-like).
In conclusion, our results confirm that the LDG pool in CKD is composed by two distinct populations, 
CD14lowCD16+ CD15+ showing a mature neutrophil-like phenotype, whereas CD14−CD16−CD15+ exhibited a 
distinct, immature profile. Nuclear morphology was also different between LDG subsets, which may account, at 
least in part, for the differences in the SSC signal.
Discussion
Chronic inflammation, exacerbated aging and organ damage are well recognized hallmarks of CKD. Despite 
considerable advances striving to identify the exact immune cell subsets involved, a number of knowledge gaps 
are still present. Over the last decade, the study of innate immunity in CKD, and especially of granulocytes, has 
been partially neglected. However, in recent years an emerging body of evidence has highlighted a pivotal role 
for LDGs in a wide range of conditions, although, their relevance in CKD had not been studied. Herein, we have 
characterized for the first time the LDG pool in CKD, with a focus on its phenotype, heterogeneity and its clinical 
relevance as a potential biomarker. Moreover, this study provides a proof-of-concept of the significance of the 
granulocyte gene DEF3 as a surrogate marker of LDG expansion and thus, of vascular calcification in CKD.
Figure 5. Microscopy analyses of LDG subsets. (A) Enriched CD15+ cells from PBMC isolates were stained 
with CD15 (PE), CD16 (APC) and CD14 or CD10 (FITC) and nuclei were counterstained with DAPI. Surface 
expression of the markers allowed the identification of the two subsets. Four representative images are shown. 
(B) Cell morphology was analyzed by transmitted light, in combination with fluorescence channels. Two 
fields where lymphocytes could be observed were chosen to allow comparison between LDG and lymphocytes 
regarding cell size and complexity, cytoplasm distribution and nuclear morphology. Two representative images 
are shown. (C) Nuclear morphology was very heterogeneous between LDG subsets. Those CD16+ mostly 
exhibited a polymorphonuclear shape, whereas a lower degree of nuclear segmentation was observed for those 
CD16−. Z-stacks were used to visualize the nuclei complexity among different sections, which evidenced the 
existence of different lobules, if present. Two representative images are shown. Original magnification X630 for 
all the images.
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LDGs have gained notable attention because of its pro-inflammatory properties and their particular charac-
teristics16,17. However, their origin and phenotype are far from being clear. Actually, there is a notable heteroge-
neity in the scientific literature about the LDG identification17). A consensus strategy for LDG identification is 
lacking, and several markers and phenotypes have been proposed, which limits the comparison among studies. 
Despite of the huge variation in the markers proposed among studies, LDGs are usually conceived as a uniform 
population in individual studies, rather than a complex pool. Our results not only suggest that two phenotypically 
distinct LDG subsets can be distinguished but also, that they differ in terms of their clinical relevance. However, 
whether this finding could be applied to other clinical scenarios remains unknown, since the literature points to 
divergent functions of the LDG expansion in different scenarios, hence adding another layer of complexity to 
this field17,20,21. LDGs exhibiting CD14low and CD16 expression were hallmarked by their elevated expression of 
mature and terminally-differentiated granulocytes and molecules of adhesion, as well as by their higher size and 
granularity compared to their CD14/CD16negative counterparts. Interestingly, CD14lowCD16+ LDGs exhibited a 
high expression of CD10, which mirrored that of neutrophils, whereas it was absent in their CD14−CD16− coun-
terparts. Importantly, CD10 is specifically expressed by mature neutrophils at their latest stages of differentia-
tion22–24, thus pointing to differences in maturation status between both LDGs subsets. Moreover, CD10 has been 
previously found to resolve heterogeneity among granulocytes in patients with acute or chronic inflammatory 
conditions in terms of their maturation status, hence strengthening our findings25. Moreover, CD14lowCD16+ 
LDGs were hallmarked by a high expression of CD35, another well-known marker of mature neutrophils22,26 that 
is expressed in the plasma membrane after being shed from the secretory granules27, hence not only confirming 
the late maturation of this LDG subset but also suggesting a link with neutrophil degranulation. On the other 
hand, CD16−CD14− LDGs showed a higher expression of CD68, a marker of the early stage of neutrophil differ-
entiation28, and exhibited a strong correlation with DEF3 expression, a well-known marker of early granulopoie-
sis19,28,29. The opposed distribution of CD35 and DEF3A aligns with the different content of neutrophil granules 
along their differentiation stages30,31. Taken together, all these lines of evidence lead us to hypothesize that LDGs 
in CKD have different origins: whereas the CD14lowCD16+ CD15+ cells are likely to be mature degranulated 
neutrophils, their CD14−CD16−CD15+ counterparts may represent a distinct, immature subpopulation of gran-
ulocytes prematurely released from the bone marrow. The differences observed for size and granularity are in line 
with this notion. Furthermore, our findings are in line with a different pattern of mobilization between these two 
subsets (Fig. 3), hence strengthening these notions. Surprisingly, a recent paper by Sagiv and coworkers revealed 
no differences in the number of granules between low density granulocytes and mature neutrophils in cancer 
patients32, which may contradict, at least in part, our hypothesis. However, due to the phenotypic and functional 
differences of LDGs in cancer and chronic inflammatory conditions, these results must be interpreted with cau-
tion. Additionally, differences in granularity could be also attributed, at least in part, to nuclear morphology and 
plasma membrane complexity. The microscopy findings observed in this study are in agreement with this idea.
Despite being less abundant than other leukocytes and exhibiting an immature phenotype, LDGs have been 
reported to prompt innate immune mechanisms, secrete pro-inflammatory cytokines, produce reactive oxygen 
species and, more importantly, to form Neutrophil Extracellular Traps (NETs)18,33,34. In fact, their immature state 
has been related to genetic damage and genomic instability in lupus patients35, which is supposed to under-
lie its aberrant functionality. Therefore, LDGs are likely to perpetuate chronic inflammation and tissue dam-
age, two prominent features of CKD pathogenesis. LDGs exhibit an enhanced production of pro-inflammatory 
cytokines such as TNFα, IL-17 or IFNγ18,33,34. These mediators have been described to be related to CKD (immu-
no)-pathogenesis36–38. Interestingly, LDGs have been reported to impair vascular repair and promote direct 
endothelial damage18,33,39. Therefore, based on the literature, LDGs may be conceived as promising mediators of 
VC and multi-organ aging in CKD, thus warrantying further mechanistic studies in the future.
Interestingly, a recent paper has brought to light the existence of a network of trans-cortical capillaries in long 
bones that form a direct connection between the endosteal and periosteal circulations40. These vessels effectively 
transport blood and express endothelial markers that can guide neutrophil trafficking to the peripheral com-
partment. The number of these vessels as well as their activation status was determined by increases in TNFα 
expression and osteoclast activity, and autoimmune diseases affecting bone physiology led to substantial changes 
in transcortical vessel number40. Therefore, it may be hypothesized that increased trans-cortical capillaries for-
mation could account, at least in part, for the increased frequency of LDGs in peripheral blood in CKD. However, 
whether trans-cortical capillaries are increased in CKD remains to be clarified.
A remarkable finding from our study was the association between CD14−CD16−CD15+ frequency and DEF3 
expression in PBMC fractions. On one hand, DEF3 is a transcript restricted to the granulocyte lineage and as 
such, it should not be detected in PBMC fractions. Although this was the case for HC, it does not hold true for 
CKD patients since a significant proportion showed a notable upregulation of this gene. Therefore, an increased 
DEF3 expression in the PBMC fractions can be attributed to a LDG expansion, as demonstrated by our findings. 
On the other hand, DEF3 is only expressed during the intermediate (myelocyte-metamyelocyte) stage of neutro-
phil maturation28,29. The fact that the DEF3 expression was correlated with CD14−CD16−CD15+ frequency, but 
not with that of CD14lowCD16+ CD15+ cells, confirms the immature status of the former and further supports the 
differences between these two subsets revealed by the immune phenotype performed. Taken together, our find-
ings highlight a potential role of DEF3 expression as a marker of immature LDGs expansion. Although interesting 
from the mechanistic point of view, LDG quantification could be accompanied by technical and logistical limita-
tions regarding its implementation in the clinical setting, as it requires the access to flow cytometry and handling 
cell biomarkers. However, the analysis of the DEF3 expression will have several advantages as a surrogate marker 
of LDG expansion and consequently, of the presence of VC. Interestingly, DEF3 has been linked to a number of 
adverse vascular outcomes (dyslipidemias, vascular and endothelial dysfunction, cardiovascular morbidity and 
mortality)41–44, hence reinforcing this point. Unfortunately, there is a profound knowledge gap about its func-
tional involvement in the setting of these conditions.
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LDG subsets were found to be stable over time. More importantly, LDGs were expanded to a similar extent 
in CKD patients undergoing peritoneal dialysis and hemodialysis, despite exhibiting a different time on dialysis. 
These results may suggest that LDG expansion is an early phenomenon and not the result of the disease progres-
sion itself. However, the possibility that LDGs expansion may be a consequence of the inflammatory condition 
associated with CKD and/or an epiphenomenon of the dialysis itself should not be ruled out. This represents a 
limitation of the present study that must be acknowledge. Moreover, the lack of functional assays does not allow 
us to evaluate the potential contribution (and differences) of the LDGs subsets to CKD pathogenesis. Further 
studies, with different patient populations and complementary methods are needed. Due to the heterogeneity of 
LDGs functional assays and the long-lasting for time frames of the clinical endpoints analyzed, a special focus 
must be considered at this stage to make a conscientious selection of functional assays and clinical endpoints.
In conclusion, the results herein presented suggest for the first time the alterations of LDGs in CKD. The LDG 
pool in CKD patients was more complex than initially conceived, with two subsets being identified and differing 
in their phenotype, nuclear morphology and presumably origin. Moreover, our study points to immature LDG as 
potential biomarkers of VC and sheds new light into the potential role of DEF3 expression as a relevant surrogate 
marker of LDG expansion in CKD. Our findings set the bases to design further functional and prospective studies 
to gain additional insight into this topic.
Material and Methods
Ethics statement. Approval for the study was obtained from the Institutional Review Board (Comité de 
Ética Regional de Investigación Clínica, reference PI16/00113), in compliance with the Declaration of Helsinki. 
All participants gave a written informed consent prior to their inclusion in the study.
patients and controls. Our study involved 33 CKD patients on peritoneal dialysis (CKD5-PD) recruited 
from the Peritoneal Dialysis Outpatient Clinic (Unidad de Gestión Clínica de Nefrología) at the Hospital 
Universitario Central de Asturias (HUCA, Oviedo, Spain). Simultaneously, a group of 15 healthy volunteers from 
the general population was recruited as healthy controls (HC). Moreover, 16 CKD patients undergoing hemo-
dialysis (CKD5-HD) (Hemodialysis Outpatient Clinic) at HUCA and 6 HC were independently recruited as a 
replication cohort (Supplementary Table 1). Predominant CKD etiology in PD and HD patients were glomeru-
lonephritis (36.3% and 37.5%) and vascular causes (16.1% and 12.5%), with unknown etiology in 22 and 12.5% 
of patients. None of the CKD patients had a previous diagnosis of diabetes. Exclusion criteria were (i) ongoing 
immunosuppressive treatment, (ii) concomitant immune-mediated disease or cancer diagnosis, (iii) recent or 
current infection, (iv) previous CV disease, abdominal aneurism or intermittent claudication, (v) previous carotid 
surgery, (vi) pregnancy or (vii) diabetes mellitus. Vascular calcifications (VC) were measured by Kauppila scores45.
Blood samples were obtained from all study subjects by venipuncture. Automated serum biochemical 
parameters, lipid analysis and complete blood counts were immediately conducted on all the participants at the 
Laboratorio de Medicina (HUCA) using routine methods. For additional tests, serum samples were stored at 
−80 °C. Peripheral blood samples were immediately processed and peripheral blood mononuclear cells (PBMCs) 
fractions were obtained by centrifugation (1900 rpm, 20 minutes) on density gradients (Lymphosep, Lymphocyte 
Separation Medium, Biowest, Germany).
Flow cytometry. PBMCs were treated with FcR Blocking Reagent (Milteny Biotech, Germany) for 20 minutes at 
4 °C to avoid unspecific antibody binding to Fc receptors. Then, cells were incubated with CD14 FITC (Immunostep, 
Spain), CD15 PE-Cy7 (Milteny Biotech), CD16 APC-Cy7 (BioLegend, Germany) and HLA-DR PE (BD Biosciences) 
or corresponding isotype antibodies for 30 minutes at 4 °C. Cells were then washed with PBS and analyzed in a FACS 
Canto II flow cytometer (BD Biosciences) equipped with a FACS Diva 6.5 software. First, a ‘live gate’ including all 
cells subsets, and excluding debris and no cellular events, was designed. LDGs were first gated by their FSC/SSC 
properties and then, the CD15+ population was selected (total LDGs). The percentage (frequency) of each population 
was computed and referred to the ‘live gate’. Siglec8 expression was analyzed to confirm that eosinophils were not 
present within CD15+ cells, after incubating with a Siglec8 FITC (BioLegend) antibody.
For LDG phenotyping, PBMCs cells were stained as previously explained together with antibodies to gran-
ulocyte lineage-specific markers: CD11b PE (BioLegend), CD10 FITC (BioLegend), CD35 FITC (BioLegend), 
CD66b APC (BioLegend), CD31 PE (Immunostep), CD62L PE (BD Biosciences) or IFNAR1 PE (R&D, Belgium). 
The intracellular CD68 staining (CD68 PE (BioLegend)) was performed on fixed and permeabilized cells 
(Cytofix/Cytoperm Kit, BD Biosciences) after extracellular staining. Neutrophil phenotyping was performed in 
parallel for comparison with LDGs subsets. To this end, whole blood was stained following the previous protocol 
followed by red blood cell lysis using FACS Lysing Solution (BD) for 5 minutes at 4 °C. Expression levels were 
measured as the Median Fluorescence Intensity (MFI) for each marker.
Confocal experiments. CD15+ cells were enriched from PBMCs samples by immunomagnetic separa-
tion using MojoSort Streptavidin Nanobeads (BioLegend) after incubating with a biotin-conjugated anti-human 
CD15 antibody (BioLegend) following the protocol provided by the manufacturer. Enrichment yield after sort-
ing was confirmed by flow cytometry. Then, enriched CD15+ fractions were seeded in poly-L-lysine coverslips 
and incubated at 37 °C, 5% CO2 for 30 minutes. Cells were washed twice with PBS and incubated with different 
antibodies [CD16 APC (Immunostep), CD15-biotin (BioLegend) and CD14 FITC (Immunostep) or CD10 FITC 
(BioLegend)] for 1 hour at 4 °C. Parallel incubations were performed with paired isotypes for each staining. Next, 
coverslips were washed twice with PBS and cells were incubated with streptavidin-conjugated PE (Immunostep) 
for 30 minutes at 4 °C. Coverslips were washed twice and cells were fixed with a 4% paraformaldehyde solution 
for 5 minutes at 4 °C. Finally, coverslips were mounted with Fluoroshield Mounting Medium With DAPI (abcam) 
and immediately analyzed using a Leica TCS-SP8X Confocal Microscope (Leica Microsystems) using the 63X 
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objective. Images were acquired with LAS X software (Leica), which was also used to produce image overlays. To 
evaluate nuclear morphology, z-stacks were obtained from 4 μm sections and maximum projections were derived.
Gene expression analyses. Total RNA from circulating PBMCs was extracted using TRI reagent 
(Sigma-Aldrich). After reverse transcription using a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems), quantitative-real time PCR (qPCR) reactions were performed in triplicate using the Stratagene 
Mx3005P QPCR System (Agilent Technologies), Fast Start Universal Probe Master (Roche) and pre-developed 
assays (Thermo-Fisher Scientific). Quantification of human DEF3 and CD10 target genes relative to GAPDH 
expression was performed by comparing threshold cycles using the ΔΔCT method.
Cytokine quantification. Serum levels of IL-10, IL-6, IL-2, TNFα and IFNγ were measured with a 
bead-based multiplex assay (BiolegendPlex, BioLegend) analyzed in a FACS Canto II flow cytometer (BD 
Biosciences) under FACS Diva 6.5, following the protocol provided by the manufacturer. The detection limits 
were 1.2 pg/ml (IL-10 and IL-2) or 2.4 pg/ml (IL-6, TNFα and IFNγ).
Statistical analysis. Continuous variables were expressed as median (interquartile range) or mean ± stand-
ard deviation, whereas n (%) was used for categorical ones. Differences among groups were assessed by Mann 
Withney U or Kruskal-Wallis (with Dunn-Bonferroni correction for multiple comparisons) tests, as appropriate. 
Correlations were assessed by Spearman ranks’ test. Paired tests were used to evaluate differences between subsets 
from the same sample. Receiver Operating Characteristic (ROC) curves were used to evaluate the adequacy of 
LDGs subsets as biomarkers, and areas under the curve (AUC) with 95% confidence intervals (CI) and p-values 
were calculated. To evaluate the additional value of LDGs as biomarkers to conventional variables, z-scores were 
first derived from the different variables (age and time on dialysis) and combined indices were obtained by sum-
ming the individual variables. Multiple regression analyses were conducted to analyze the role of LDGs as a 
biomarker after adjusting for potential confounders. A p-value < 0.050 was considered as statistically significant. 
Statistical analyses were performed with SPSS 24.0 and GraphPad Prism 5.0 for Windows.
Data Availability
No datasets were generated or analyzed during the current study.
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